Atherosclerosis Drugs - Global Strategic Business Report

The global market for Atherosclerosis Drugs was estimated at US$21.3 Billion in 2024 and is projected to reach US$25.3 Billion by 2030, growing at a CAGR of 3.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Atherosclerosis Drugs market.

Global Atherosclerosis Drugs Market - Key Trends and Drivers Summarized

Atherosclerosis is a chronic condition characterized by the accumulation of plaque within the arteries, leading to narrowed and stiffened artery walls which can impede blood flow or lead to thrombosis. Atherosclerosis is a principal cause of cardiovascular diseases (CVDs), such as heart attacks and strokes, which are among the leading causes of death worldwide. Drugs used to treat atherosclerosis are primarily aimed at reducing the underlying causes of the condition, such as high levels of cholesterol and triglycerides in the blood, and managing risk factors like high blood pressure. Statins are the most widely used class of drugs in this category and work by inhibiting the enzyme involved in cholesterol synthesis, thereby lowering cholesterol levels in the blood. Other drug classes include fibrates, niacin, bile acid sequestrants, and newer agents like PCSK9 inhibitors, which significantly reduce low-density lipoprotein (LDL) cholesterol and are particularly useful in patients with genetic lipid disorders or those who do not respond adequately to statins.

Recent advancements in the treatment of atherosclerosis focus on a more comprehensive approach to cardiovascular risk reduction, beyond merely managing cholesterol levels. This includes the development of drugs that target inflammatory processes which contribute to plaque build-up and instability. For instance, anti-inflammatory treatments such as canakinumab have shown potential in reducing the risk of cardiovascular events by targeting specific inflammatory pathways associated with atherosclerosis. Additionally, the integration of precision medicine into treatment protocols allows for tailored therapeutic strategies based on individual genetic profiles, improving the efficacy and safety of drug therapies. The advent of gene editing technologies and RNA therapies also holds promise in directly modifying the contributors to atherosclerosis at the molecular level, potentially offering more permanent solutions than traditional pharmaceutical approaches.

The growth in the atherosclerosis drugs market is driven by several factors, including the increasing prevalence of cardiovascular diseases globally, heightened awareness and proactive management of heart health among the general population, and significant advancements in drug research and development. An aging global population and lifestyle factors such as poor diet, lack of physical activity, and smoking contribute to the rising incidence of atherosclerosis and related cardiovascular conditions, fueling demand for effective treatments. The pharmaceutical industry`s commitment to innovation in this area is evidenced by substantial investments in R&D for developing more effective and safer therapies, with a particular emphasis on addressing drug resistance and reducing side effects associated with long-term use. Furthermore, government initiatives to reduce the burden of cardiovascular diseases through public health campaigns and supportive policies promote the use of preventive and therapeutic drugs. As patient education improves and screening becomes more widespread, the early adoption of drug therapies to manage risk factors effectively is expected to rise, further propelling market growth.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Antiplatelet & Anticoagulants segment, which is expected to reach US$13.2 Billion by 2030 with a CAGR of a 3.8%. The ACE Inhibitors segment is also set to grow at 2.3% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $5.8 Billion in 2024, and China, forecasted to grow at an impressive 5.5% CAGR to reach $5.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Atherosclerosis Drugs Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Atherosclerosis Drugs Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Atherosclerosis Drugs Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AdvaCare Pharma, Astrazeneca Pharmaceuticals LP, Cayman Chemical Company, Crescent Pharma Ltd, Kowa Co., Ltd. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 56 companies featured in this Atherosclerosis Drugs market report include:

• AdvaCare Pharma
• Astrazeneca Pharmaceuticals LP
• Cayman Chemical Company
• Crescent Pharma Ltd
• Kowa Co., Ltd.
• Lupin Pharmaceuticals, Inc
• MilliporeSigma
• Novartis International AG
• Pfizer, Inc.
• Rosemont Pharmaceuticals Limited
• Sterling Biotech Ltd
• Teva Pharmaceuticals USA, Inc.
• Tokyo Chemical Industry Co., Ltd.
• Viatris, Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.